Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of June 2022, with a specific transaction date of June 7, 2022. The report serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a periodic financial results report.
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific insider transaction:
- Instrument: American Depositary Shares (ADSs)
- Transaction Type: Acquisition within an Executive Supplemental Savings Plan
- Price: $44.2500 per ADS
- Volume: 1,164.026 ADSs
Material Changes
There are no material changes to the company's financial position or operations reported in this document. The filing details a single acquisition event by Dr. H. Barron, Chief Scientific Officer and President, R&D, executed on the New York Stock Exchange.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is strictly a regulatory disclosure of an insider trading event.
Key Facts for Investor Verification
- Dr. H. Barron acquired 1,164.026 GSK ADSs at $44.25 on June 7, 2022.
- The transaction was part of the GSK Executive Supplemental Savings Plan.
- This filing does not contain quarterly or annual financial performance data.